Lucid Discovery Platform
Multi-omics insights, powered by 100% of the genome
Lucid combines proprietary structural variant calling, AI-based prioritization, and multi-omics integration across genomics, transcriptomics, and proteomics. We map 3D genome architecture to connect distant regulatory elements with their target genes.
This enables the discovery of disease-driving mechanisms that are missed by conventional tools and supports faster, more accurate identification of biomarkers and drug targets.
Only 1 in 10 drugs make it to market
Genomics unlocks higher success rates in clinical trials
Genomics-guided drugs are 2.6× more likely to reach approval, raising success rates from under 10% to around 20%.
Lucid's team has been at the forefront of non-coding and structural variant research, well before these regions gained wider recognition. We bring deep expertise in uncovering regulatory drivers that conventional pipelines miss.
Our Services
Biomarker Discovery
Uncover novel, functional biomarkers in non-coding and structurally complex genomic regions that are inaccessible to standard analytical panels.
Link non-coding signals to disease phenotypes.
Identify variants with regulatory potential
Improve patient stratification for clinical trials.